In KEYNOTE-042 clinical trial, front-line pembrolizumab therapy for metastatic NSCLC patients who have positive PD-L1 expression (TPS ≥ 1%) presents better clinical outcomes compared with platinum-based chemotherapy [11]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.